肥胖与哮喘:肥胖在整个2型炎症谱中导致并加重哮喘
肥胖通过脂肪因子信号、ILC2-嗜酸性粒细胞-巨噬细胞交互、系统性低度炎症、代谢紊乱及机械效应影响哮喘,应视为可治疗特征。减重可改善T2高和T2低哮喘的症状、肺功能及急性发作风险。
要点
- 肥胖是哮喘最常见共病之一,与更差控制和更高急性发作风险相关。
- 肥胖相关哮喘不限于T2低表型,而是异质性病症。
- 减重(生活方式、药物或减重手术)可改善T2高和T2低哮喘的预后。
核心结论
- 肥胖应被视为哮喘的可治疗特征,减重可改善T2高和T2低哮喘的症状、肺功能及急性发作风险。
研究设计与样本
- 综述类文章,未报告系统检索范围。
主要发现
- 哮喘临床试验和登记中成人平均BMI为28 kg·m-2至30 kg·m-2,高达70%患者超重或肥胖。
- 肥胖通过脂肪因子信号失调、ILC2-嗜酸性粒细胞-巨噬细胞交互受损、系统性低度炎症、代谢紊乱及机械效应影响哮喘。
- 肥胖哮喘患者使用抗T2生物制剂减少急性发作的幅度与瘦者相似,但症状和肺功能改善可变。
- 减重(生活方式、药物或减重手术)改善T2高和T2低哮喘的症状、肺功能及急性发作风险。
临床怎么用
- 临床应将肥胖作为哮喘的可治疗特征进行管理。
- 对肥胖哮喘患者可考虑减重干预以改善症状、肺功能和急性发作风险。
- 抗T2生物制剂对肥胖哮喘患者的急性发作减少效果与瘦者相似,但需注意症状和肺功能改善可能不一。
局限性
- 未来需专门针对哮喘合并肥胖患者开展GLP-1和双GLP-1/GIP激动剂的随机安慰剂对照试验。
- 需阐明肥胖如何改变炎症内型和治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity affects more than 650 million adults worldwide, with prevalence continuing to rise across all age groups and continents. This trend has important implications for asthma: individuals with obesity have a 30-50% higher risk of developing asthma, and obesity is highly prevalent among people with established disease. Mean body mass index in clinical trials and registries of adults with asthma consistently ranges from 28 kg·m-2 to 30 kg·m-2, with up to 70% of patients being overweight or obese. These numbers highlight obesity as one of the most common comorbidities in asthma, consistently associated with poorer asthma control and a higher risk of exacerbations. Although obesity-associated asthma is often described as type-2 (T2)-low phenotype, it is increasingly recognised as a heterogeneous condition not restricted to a single phenotype. Excess adiposity influences asthma through multiple mechanisms, including dysregulated adipokine signalling, impaired innate lymphoid cells type 2 (ILC2)-eosinophil-macrophage cross-talk in adipose tissue, systemic low-grade inflammation, metabolic dysfunction, and mechanical effects on lung volumes. This diversity complicates diagnosis, endotyping, and treatment stratification. Obesity should therefore be considered a treatable trait in asthma. Weight reduction (through lifestyle interventions, pharmacotherapy or bariatric surgery) improves symptoms, lung function, and exacerbation risk across both T2-high and T2-low asthma. Importantly, patients with obesity experience similar reductions in exacerbations with anti-T2 biologics as their lean counterparts, though improvements in symptoms and lung function are variable. Future research should prioritise randomised, placebo-controlled trials evaluating glucagon-like peptide (GLP)-1 and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-agonist therapies specifically in patients with asthma and obesity, and elucidate how obesity modifies inflammatory endotypes and treatment responses.
引用
- Riemann, Matthys, Maes, et al. Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum. Eur Respir J. 2026. PMID: 41713950. doi:10.1183/13993003.02687-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。